Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q2 2026
Jazz Pharmaceuticals (JAZZ) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 3, 2026
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2B for the second quarter 2026 (Q2 2026), +16% from a year earlier and +13% from the quarter before. Operating margin was 20.5%, net earnings $193M (16.0% of revenue).
Jazz Pharmaceuticals, Q2 2026: revenue $1.2B (+16% year over year), operating margin 20.5%, net earnings $193M, operating cash flow $416M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2B | +13% | +16% |
| Operating profit | $248M | -26% | — |
| Net earnings | $193M | -34% | — |
| Operating cash flow | $416M | +2% | +368% |
| Free cash flow | $398M | +2% | +424% |
What changed
Revenue was $1.2B in Q2 2026, up 16% year over year and up 13% from the previous quarter. Xywav was the largest line at 39% of revenue. Xywav added $0.06B year over year (up 13%), 34% of the total change. Vyxeos declined 30%.
Operating profit was $0.25B, a 20.5% margin (up 86.2 points year over year). Total costs fell 45% while revenue rose 16%. Net earnings were $0.19B. The effective tax rate was 8.6%.
Operating cash flow was $0.42B (up 368% year over year), 216% of net earnings. Non-cash charges added back $0.18B of depreciation and amortization and $0.07B of share-based compensation. Working capital and other items used $0.03B. Capital expenditures of $0.02B left free cash flow of $0.40B.
Questions
What was Jazz Pharmaceuticals' revenue in the second quarter 2026?
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2B for the second quarter 2026 (Q2 2026), +16% from a year earlier and +13% from the quarter before.
Was Jazz Pharmaceuticals profitable in the second quarter 2026?
Operating profit was $248M (20.5% of revenue) and net earnings $193M.